OR WAIT null SECS
Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.
Stevanato Group, an Italian provider of drug containment, drug delivery, and diagnostic solutions, announced a collaboration with Recipharm, a Swedish contract development and manufacturing organization, on March 16, 2023. Under the agreement, Stevanato will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.
Stevanato will provide and manufacture its proprietary glass pre-fillable syringe, Alba, assembled with the integrated spray module of Recipharm’s soft mist inhaler technology, the Pre-Filled Syringe Inhaler (PSFI). According to a company press release, the goal of this partnership is to deliver drug products more efficiently to the respiratory airways, as well as provide biopharma companies with a containment solution that features enhanced stability and safety.
“By leveraging Stevanato Group's integrated capabilities, from plastic injection molding and assembly capabilities to comprehensive scientific and analytical support services, we will be able to offer a turnkey solution, and accelerate and de-risk our pharmaceutical customers’ development programs,” said Bernhard Muellinger, general manager and chief operational officer, Resyca (a joint venture between Recipharm and Medspray), in the release. “This is particularly true for novel inhaled biological products.”
“Biopharma companies are advancing patient care with new, innovative treatments, particularly in biologics and mRNA [messenger RNA] therapies,” said Mauro Stocchi, chief business officer, Stevanto Group, in the release. “These products require specialized, high-performance drug containment systems, like our Alba syringe platform, together with patient-centric drug delivery devices [such as] the PFSI.”